TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8521433
Drug: 1-min active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-min active mouthrinse with toothpaste-foam combined with 10 ml of water after brushing for 2 min
Study: 8521433
Drug: 3 thorough
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 thorough rinsings of approximately 15 ml water each after brushing for 2 min
Study: 2089286
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with 400 mg/day of cimetidine for 1 year
Study: 2089286
Drug: Seasonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal therapy with 400 mg/day of cimetidine for 4 months a year
Study: 27852613
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g vitamin C-enriched gelatin
Study: 27852613
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g vitamin C-enriched gelatin
Study: 25060839
Drug: Intranasal buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buprenorphine (8 mg)
Study: 25060839
Drug: Intranasal buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buprenorphine (16 mg)
Study: 25060839
Drug: Buprenorphine/naloxone (8/2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone (8/2, 8/8, 8/16, 16/4 mg)
Study: 7407606
Drug: Naloxone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (4 mg)
Study: 25060839
Drug: Heroin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin (100 mg)
Study: 21720299
Drug: sinuforte (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: sinuforte (one dose administered daily into each half of the nasal cavity)
Study: 19854960
Drug: Sonographically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonographically guided injections of hyaluronic acid (HA)
Study: 19854960
Drug: Blind injections
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind injections of hyaluronic acid (HA)
Study: 16412748
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of letrozole
Study: 16412748
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of letrozole
Study: 15260909
Drug: Venlafaxine 37.5
Normalized name: venlafaxine 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 37.5 mg b.i.d.
Study: 15260909
Drug: Dothiepin 25
Normalized name: dothiepin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin 25 mg mane followed by 50 mg nocte
Study: 8095383
Drug: Atracurium (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.4 mg.kg‐1 BW)
Study: 8095383
Drug: Vecuronium (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.08 mg.kg‐1 BW)
Study: 27475844
Drug: Thrombectomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombectomy and intracoronary administration of tirofiban (Group A)
Study: 24930201
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus a 12-week post-exacerbation pulmonary rehabilitation (PEPR) programme
Study: 24930201
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment without pulmonary rehabilitation (CTWPR)
Study: 20127562
Drug: Low-dose lomitapide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lomitapide (AEGR-733)
Study: 20127562
Drug: High-dose MTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose MTP inhibitors (not specified)
Study: 14977161
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray
Study: 29423865
Drug: High-volume corticosteroid
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume corticosteroid injections (HCI) - 10 mL total volume of 1% lidocaine plus 40 mg TA
Study: 29423865
Drug: Low-volume corticosteroid
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume corticosteroid injections (LCI) - 4 mL total volume of 1% lidocaine plus 40 mg TA
Study: 22245891
Drug: Vandetanib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib (both doses)
Study: 10227009
Drug: 1.25 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/day Tibolone
Study: 10227009
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day Tibolone
Study: 8880942
Drug: d-amphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (10 mg BID)
Study: 8880942
Drug: placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (0 mg BID)
Study: 6394505
Drug: Intravenous penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous penicillin therapy
Study: 6394505
Drug: Oral penicillin
Normalized name: penicillin G Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral penicillin therapy
Study: 31479120
Drug: Intramyocardial injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injection of mesenchymal precursor cells
Study: 26861164
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration after four prior administrations of apomorphine
Study: 26861164
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration after two, three, or four prior administrations of apomorphine
Study: 26861164
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration for the first time
Study: 20597828
Drug: Sensor-augmented insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensor-augmented insulin pump therapy (SAP group)
Study: 16266358
Drug: Topiramate (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (800 mg daily)
Study: 14562135
Drug: Acupuncture specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture specific against erectile dysfunction (treatment group)
Study: 14562135
Drug: Simultaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous treatment with 50 mg sildenafil
Study: 29108526
Drug: Sleep Treatment
Normalized name: Sleep
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sleep Treatment at Acute Crisis (STAC) plus Standard Care (SC)
Study: 27082758
Drug: Oral Instructions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Instructions to Third Person
Study: 24126198
Drug: Adhesive patch
Normalized name: ADHESIVE PATCH, MEDICATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adhesive patch method
Study: 17604143
Drug: Curcuminoids at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids at 2000 mg/day for 7 weeks
Study: 11114313
Drug: Fludarabine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (25 mg/m² IV daily for 5 days every 28 days)
Study: 11114313
Drug: Chlorambucil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (40 mg/m² orally every 28 days)
Study: 11114313
Drug: Fludarabine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (25 mg/m²)
Study: 11114313
Drug: Chlorambucil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (40 mg/m²)
Study: 8369211
Drug: Nickel sulphate
Normalized name: Nickel sulphate
DrugBank: Nickel sulfate (DB14180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nickel sulphate patch tests with a 10-step nickel sulphate dilution series (TRUE test)
Study: 8369211
Drug: Nickel sulphate
Normalized name: Nickel sulphate
DrugBank: Nickel sulfate (DB14180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nickel sulphate patch tests with high concentrations
Study: 3790957
Drug: 1 per
Normalized name: ALOE VESTA 2-N-1 PERINEAL CLEANSER SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 per cent topical povidone-iodine solution in addition to systemic antibiotics (gentamicin and metronidazole)
Study: 3790957
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics (gentamicin and metronidazole) without topical agent
Study: 27681601
Drug: Pre-operative DVD
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative DVD and standard preparation
Study: 23990706
Drug: Etomidate emulsion
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate emulsion group 1 (E1) - 10 μg · kg(‐1) · min(‐1) combined with remifentanil (0.1 μg · kg(‐1) · min(‐1))
Study: 23990706
Drug: Etomidate emulsion
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate emulsion group 2 (E2) - 15 μg · kg(‐1) · min(‐1) combined with remifentanil (0.2 μg · kg(‐1) · min(‐1))
Study: 23990706
Drug: Etomidate emulsion
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate emulsion group 3 (E3) - 20 μg · kg(‐1) · min(‐1) combined with remifentanil (0.2 μg · kg(‐1) · min(‐1))
Study: 23990706
Drug: Propofol group
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol group (P group) - 610 mg · kg(‐1) · h(‐1)
Study: 16778652
Drug: PMMA implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMMA implant
Study: 19248868
Drug: Multifamily therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifamily therapy plus psychoeducation (n=15)
Study: 16729277
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg ibandronate every 2 months
Study: 16729277
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg ibandronate every 3 months
Study: 16729277
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg oral ibandronate daily
Study: 16729277
Drug: All intravenous
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All intravenous regimens
Study: 12970329
Drug: Quinapril 40
Normalized name: quinapril 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 40 mg daily
Study: 2656929
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin therapy
Study: 30314978
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg/d
Study: 25923485
Drug: Bilberry extract
Normalized name: Bilberry Extract
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilberry extract (BE) 480 mg/day
Study: 23592479
Drug: Ghrelin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin administration (300 min, supraphysiological dose)
Study: 21762197
Drug: MTZ+AMX (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTZ+AMX (500 mg t.i.d.) for 14 days
Study: 21762197
Drug: MTZ (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTZ (400 mg t.i.d.) for 14 days
Study: 9249100
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 2 mg x kg(‐1) x h(‐1)
Study: 12831948
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 1.0 mg of Cu/2000 kcal and 99 mg of Mg/2000 kcal for 81 days
Study: 12831948
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 1.0 mg of Cu/2000 kcal and 399 mg of Mg/2000 kcal for 81 days
Study: 12831948
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 3.0 mg of Cu/2000 kcal and 99 mg of Mg/2000 kcal for 81 days
Study: 12831948
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 3.0 mg of Cu/2000 kcal and 399 mg of Mg/2000 kcal for 81 days
Study: 12831948
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of Mg/d
Study: 9155573
Drug: Omeprazole (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (8 mg/hour after a bolus of 80 mg)
Study: 9155573
Drug: Ranitidine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (0.25 mg/kg/hour after a bolus of 50 mg)
Study: 3297481
Drug: Kathon CG
Normalized name: CG-200745
DrugBank: CG-200745 (DB12259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kathon CG 15 ppm active ingredient in a leave-on body lotion
Study: 3297481
Drug: Control lotion
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control lotion without Kathon CG
Study: 31263013
Drug: Artificial tears
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tears gel (Vidisic Gel; Bausch and Lomb)
Study: 27740878
Drug: AZD5423 (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5423 (selective glucocorticoid receptor modulator)
Study: 20606083
Drug: Pazopanib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (800 mg once daily)
Study: 23964934
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg once daily for 4 weeks, followed by 2 weeks without treatment)
Study: 22024490
Drug: NUTRIOSE 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE 8 g/d
Study: 22024490
Drug: NUTRIOSE 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE 14 g/d
Study: 22024490
Drug: NUTRIOSE 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE 18 g/d
Study: 22024490
Drug: NUTRIOSE 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE 24 g/d
Study: 18804132
Drug: IC51 vaccine
Normalized name: Japanese encephalitis vaccine IC51
DrugBank: Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC51 vaccine in TBE ELISA-positive subjects
Study: 18804132
Drug: IC51 vaccine
Normalized name: Japanese encephalitis vaccine IC51
DrugBank: Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC51 vaccine in TBE ELISA-negative subjects
Study: 14509504
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue (3 ml applied to the dissected mediastinum)
Study: 10232311
Drug: Co-trimoxazole (trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (trimethoprim 160 mg, sulphamethoxazole 800 mg) daily
Study: 6880226
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g per day for 8 weeks followed by surgery if symptomatic recurrence occurs
Study: 6880226
Drug: Repeated courses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated courses of cimetidine 1 g per day for 8 weeks in case of recurrence
Study: 6880226
Drug: Cimetidine treatment
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine treatment (single vs repeated courses)
Study: 12959636
Drug: Aspirin 80
Normalized name: aspirin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 80 mg/day
Study: 2876664
Drug: Aspirin 40
Normalized name: aspirin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 40 mg/day
Study: 2876664
Drug: Aspirin 40
Normalized name: aspirin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 40 mg/day and 80 mg/day
Study: 30054049
Drug: Single-agent cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-agent cetuximab (Arm-A)
Study: 16921044
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic therapy
Study: 18504550
Drug: Tissue factor
Normalized name: Tissue factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue factor pathway inhibitor
Study: 10770187
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg) for 5 yr (group I)
Study: 10770187
Drug: Alendronate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (20 mg) for 2 yr followed by 3 yr off therapy (group III)
Study: 10770187
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 3 yr followed by alendronate (5 mg) for 2 yr (group II)
Study: 8393108
Drug: Doxycycline (Do)
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline (Do) 200 mg on the first day and 100 mg for 4 days, followed by Amoxicillin/Clavulanate potassium (Au) 500 mg 3 times daily for 5 days
Study: 27048836
Drug: Oral dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dietary supplementation of pasteurised Bacteroides xylanisolvens DSM 23964 for 8 weeks
Study: 24502652
Drug: Short-term professional
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term professional oral health care (once per week for 1 month)
Study: 23564179
Drug: Oxytocin 40
Normalized name: oxytocin 40 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin 40 IU nasal spray
Study: 18847422
Drug: Biocompatible bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocompatible bicarbonate solution
Study: 18847422
Drug: Biocompatible lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocompatible lactate solution
Study: 18847422
Drug: Bicarbonate/lactate solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate/lactate solutions
Study: 25746151
Drug: Biocompatible solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocompatible solutions
Study: 18847422
Drug: New solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: New solutions
Study: 18847422
Drug: Dialysis solutions
Normalized name: dialysis solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis solutions with higher glucose degradation products
Study: 16635293
Drug: Lamivudine treatment
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine treatment group (100 mg orally every day)
Study: 16635293
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional supporting treatment)
Study: 16635293
Drug: Lamivudine treatment
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine treatment group
Study: 12583554
Drug: Cefazolin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (2 g)
Study: 10980913
Drug: Low-dose fish
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fish oil (875 mg capsules containing 850 to 882 mg EPA and DHA)
Study: 3928960
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide with forced diuresis (Group A)
Study: 3928960
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide without forced diuresis (Group B)
Study: 9177376
Drug: Tibolone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 1.25 mg (n = 36, 29 completed)
Study: 9177376
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg (n = 35, 28 completed)
Study: 8257146
Drug: Rufloxacin taken
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rufloxacin taken 5 min after antacid (Maalox 30 ml)
Study: 8257146
Drug: Rufloxacin taken
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rufloxacin taken 4 h before antacid (Maalox 30 ml)
Study: 4041513
Drug: nonsedating doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: nonsedating doses of diazepam
Study: 30231626
Drug: erenumab 70
Normalized name: Erenumab 70 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: erenumab 70 mg
Study: 30231626
Drug: erenumab 140
Normalized name: Erenumab 140 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: erenumab 140 mg
Study: 30253049
Drug: all-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all-trans retinoic acid/Clobetasol Propionate Compound Ointment
Study: 30253049
Drug: calcipotriol/betamethasone dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcipotriol/betamethasone dipropionate ointment
Study: 26559681
Drug: B9 (10mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: B9 (10mg/day orally) for 2 months, followed by B12 (1000 μg) for 2 months, then B9 + B12 for 2 months (Group A)
Study: 21088807
Drug: L‐T4 replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐T4 replacement
Study: 17389557
Drug: darunavir (TMC114)
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: darunavir (TMC114) coadministered with low-dose ritonavir under fasted conditions
Study: 17389557
Drug: darunavir (TMC114)
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: darunavir (TMC114) coadministered with low-dose ritonavir after a standard meal
Study: 16372585
Drug: Sparfloxacin (SPFX)
DrugBank: Sparfloxacin (DB01208)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sparfloxacin (SPFX) 200 mg/day for 21 days
Study: 16372585
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment for 21 days
Study: 11953688
Drug: Octreotide 500
Normalized name: 1 ML octreotide 500 MCG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 500 microg thrice daily